Nanoemulsion therapeutic compositions and methods of using the same

Abstract

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia ) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

What is claimed is: 
     
         1 . A method of treating a wound infection comprising administering a composition comprising a therapeutically effective amount of a nanoemulsion to the wound infection, wherein the nanoemulsion comprises:
 1. 30-90%, 60-80%, or 60-70% by volume oil;   2. 3-15% by volume solvent; wherein said solvent is selected from the group consisting of ethanol and glycerol;   3. 0.05-10.0% by volume non-ionic surfactant and 0.001-5.0% by volume cationic surfactant;   4. ethylenediaminetetraacetic acid (EDTA); and   5. water.   
     
     
         2 . The method of  claim 1 , wherein the composition kills microbes or inhibits microbial growth within the wound infection in the absence of increased inflammation and edema at the site of the wound. 
     
     
         3 . The method of  claim 2 , wherein the composition kills or inhibits growth of a pathogenic microbe. 
     
     
         4 . The method of  claim 3 , wherein the pathogenic microbe is a bacterium. 
     
     
         5 . The method of  claim 4 , wherein the bacterium is  Staphylococcus aureus.    
     
     
         6 . The method of  claim 5 , wherein the  Staphylococcus aureus  is antibiotic resistant. 
     
     
         7 . The method of  claim 3 , wherein the bacterium is  Pseudomonas aeruginosa.    
     
     
         8 . The method of  claim 3 , wherein the pathogenic microbe is a virus. 
     
     
         9 . The method of  claim 2 , wherein the composition kills or inhibits growth of a microbe selected from the group consisting of a bacterium, an archaea, a fungus, a protozoan, and a  mycoplasma.    
     
     
         10 . The method of  claim 1 , wherein the composition is co-administered with a bioactive agent. 
     
     
         11 . The method of  claim 1 , wherein the nanoemulsion comprises:
 a) water;   b) polyoxyethylenesorbitan monolaurate;   c) glycerol or ethanol;   d) oil;   e) dimethyl benzyl ammonium chloride; and   f) ethylenediaminetetraacetic acid (EDTA).   
     
     
         12 . The method of  claim 1 , wherein the nanoemulsion comprises:
 a) water;   b) a non-ionic surfactant selected from the group consisting of polyoxyethylenesorbitan monolaurate, polyoxyethylenesorbitan monooleate, and a poloxamer;   c) glycerol or ethanol;   d) oil;   e) a cationic surfactant selected from the group consisting of cetylpyridinium chloride (CPC), benzalkonium chloride, and alkyl dimethyl benzyl ammonium chloride; and   f) ethylenediaminetetraacetic acid (EDTA).   
     
     
         13 . The method of  claim 1 , wherein the nanoemulsion has a mean particle size of 0.2-0.8 microns. 
     
     
         14 . The method of  claim 1 , wherein the nanoemulsion has a mean particle size less than 0.5 microns. 
     
     
         15 . The method of  claim 1 , further comprising co-administering an antimicrobial agent to the wound. 
     
     
         16 . The method of  claim 15 , wherein the antimicrobial agent is an antibiotic. 
     
     
         17 . The method of  claim 1 , wherein the nanoemulsion comprises:
 a) water;   b) 0.05-10.0% polyoxyethylene sorbitan monolaurate;   c) 3-15% glycerol;   d) oil;   e) 0.001-5.0% benzalkonium chloride; and   f) ethylenediaminetetraacetic acid (EDTA).   
     
     
         18 . The method of  claim 1 , wherein the site of the wound is on the skin. 
     
     
         19 . The method of  claim 1 , wherein the site of the wound is in the lung or respiratory tract. 
     
     
         20 . The method of  claim 1 , wherein the site of the wound is on a mucosal surface.